Lineage Cell Therapeutics Inc
$ 1.90
4.40%
25 Feb - close price
- Market Cap 437,622,000 USD
- Current Price $ 1.90
- High / Low $ 1.90 / 1.82
- Stock P/E N/A
- Book Value 0.10
- EPS -0.29
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -1.58 %
- 52 Week High 2.09
- 52 Week Low 0.36
About
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Analyst Target Price
$4.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-12 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.13 | -0.13 | -0.02 | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 |
| Estimated EPS | -0.02 | -0.03 | -0.028 | -0.03 | -0.04 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Surprise | -0.11 | -0.1 | 0.008 | 0.02 | 0.02 | 0.02 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.01 |
| Surprise Percentage | -550% | -333.3333% | 28.5714% | 66.6667% | 50% | 40% | 0% | 25% | 0% | 25% | 25% | 25% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.3125 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LCTX
2026-02-26 20:52:13
Lineage Cell Therapeutics, Inc. announced that it will report its fourth-quarter and full-year 2025 financial and operating results on Thursday, March 5, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a business update. This report will cover the clinical-stage biotechnology company's progress with its allogeneic cell therapies for various serious medical conditions.
2026-02-09 16:28:52
D. Boral Capital has reiterated a "Buy" rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) with a $2.00 price target, alongside HC Wainwright's "Buy" rating and $9.00 target. The clinical-stage biotech company, specializing in allogeneic cell therapies, reported Q3 revenue of $3.68 million, surpassing estimates, though EPS missed expectations, and it remains unprofitable. The stock opened at $1.70, with institutional investors holding 62.47% of shares.
2026-02-09 12:58:56
Lineage Cell Therapeutics (LCTX) has received a consistent "Buy" rating from D. Boral Capital, with analyst Jason Kolbert maintaining a price target of $2.00. This stable outlook indicates continued confidence in the biotechnology company's potential. Despite GuruFocus's estimated GF Value suggesting a slight downside, the average target price from 6 analysts implies a significant upside of 145.10% from the current price.
2026-02-02 18:58:42
Lineage Cell Therapeutics announced it achieved its first development milestone under its partnership with Roche for the OpRegen program. This achievement triggers an undisclosed milestone payment to Lineage Cell, strengthening the collaboration between the two companies.
2026-01-29 19:28:57
The healthcare sector is undergoing a significant transformation towards regenerative medicine, with the "Longevity Infrastructure" market projected to reach $27 trillion by 2030. This shift is driving a surge in longevity biotech stocks as companies focus on cell restoration and advanced therapies. The article highlights several key players like Avant Technologies, MannKind, Altimmune, Lineage Cell Therapeutics, and Arrowhead Pharmaceuticals, detailing their innovative approaches and the substantial market opportunities they address in diabetes, metabolic syndrome, and age-related diseases.
2026-01-29 18:58:42
The longevity biotech sector is experiencing a surge in investment, with global capital rotating into "Longevity Infrastructure" projected to reach $27 trillion by 2030, driven by a shift towards regenerative medicine and cell restoration. Companies like Avant Technologies, MannKind, Altimmune, Lineage Cell Therapeutics, and Arrowhead Pharmaceuticals are at the forefront, focusing on advanced cell therapies, gene-targeted treatments, and AI-driven drug discovery. This paradigm shift aims to address significant health challenges like diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and age-related diseases with curative infrastructure rather than mere symptom management.
